Shoji Okinaga
-
- Lung Cancer Treatments and Mutations 10
- Oncology top 2%
- Lung Cancer Research Studies 9
- Colorectal Cancer Treatments and Studies 8
-
- Thermal Regulation in Medicine 5
- Immunology top 5%
- Cell Biology top 5%
- melanin and skin pigmentation 5
-
- Heme Oxygenase-1 and Carbon Monoxide 10
- RNA regulation and disease 5
-
- Asthma and respiratory diseases 8
Shoji Okinaga
47 papers receiving 3.7k citations
Hit Papers
Peers
Comparison fields: 5 of 129
- Pulmonary and Respiratory Medicine 1.6k
- Oncology 1.1k
- Critical Care and Intensive Care Medicine 178
- Immunology 642
- Cell Biology 440
Countries citing papers authored by Shoji Okinaga
This map shows the geographic impact of Shoji Okinaga's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shoji Okinaga with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shoji Okinaga more than expected).
Fields of papers citing papers by Shoji Okinaga
This network shows the impact of papers produced by Shoji Okinaga. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shoji Okinaga. The network helps show where Shoji Okinaga may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Shoji Okinaga, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2017 | 0 | |
| 2 | 2016 | 31 | |
| 3 | 2016 | 5 | |
| 4 | 2015 | 23 | |
| 5 | 2013 | 34 | |
| 6 | Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin–paclitaxel for chemo-naïve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002)breakdown → | 2012 | 427 |
| 7 | 2011 | 2 | |
| 8 | 2009 | 369 | |
| 9 | 2009 | 156 | |
| 10 | Nitroglycerin treatment may increase response to docetaxel and carboplatin regimen via inhibitions of hypoxia-inducible factor-1 pathway and P-glycoprotein in patients with lung adenocarcinoma | 2006 | 9 |
| 11 | 2005 | 56 | |
| 12 | 2002 | 117 | |
| 13 | 2001 | 1 | |
| 14 | 2000 | 471 | |
| 15 | 1998 | 26 | |
| 16 | 1998 | 9 | |
| 17 | 1997 | 231 | |
| 18 | 1996 | 5 | |
| 19 | 1991 | 41 | |
| 20 | 1989 | 168 |
About Shoji Okinaga
Shoji Okinaga is a scholar working on Critical Care and Intensive Care Medicine, Endocrine and Autonomic Systems and Emergency Medical Services, having authored 49 papers that have together received 3.8k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (10 papers), Heme Oxygenase-1 and Carbon Monoxide (10 papers), Lung Cancer Research Studies (9 papers), Colorectal Cancer Treatments and Studies (8 papers), Asthma and respiratory diseases (8 papers), Thermal Regulation in Medicine (5 papers), RNA regulation and disease (5 papers) and melanin and skin pigmentation (5 papers). The work is most often cited by research in Pulmonary and Respiratory Medicine (1.6k citations), Oncology (1.1k citations) and Critical Care and Intensive Care Medicine (178 citations). Shoji Okinaga has collaborated with scholars based in Japan, South Korea and United States. Frequent co-authors include Shigeki Shibahara, Hidetada Sasaki, Mutsuo Yamaya, Kiyohisa Sekizawa, Norihiro Yamada, Katsutoshi Nakayama, Norma P. Gerard, Takashi Ohrui, Koichi Hagiwara and Makoto Maemondo.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.